Fenofibrate for Diabetic Retinopathy (Protocol AF Trial)

"Fenofibrate 160mg receives a safety rating of 3 due to Phase 3 clinical trial data, which demonstrates both efficacy and safety."

"The aforementioned clinical trial, as seen on clinicaltrials.gov, is looking for volunteers. This trial was originally posted on 3/5/2021 and was updated as recently as 10/13/2022."

"The efficacy of fenofibrate 160mg was first researched in 2009 by University of Ioannina Medical School. In the years since, a total of 18314 clinical trials have been completed. Fenofibrate is currently being trialled in 9 active studies, the majority of which are based in Ayer, Massachusetts."

"This clinical trial is accepting 910 participants, between the ages of 18 and 80 who currently have diabetic retinopathy. It is required that patients also meet the following criteria: Key Inclusion Criteria, Age ≥18 years and < 80 years., Mild to moderately severe NPDR (defined by ETDRS DR severity level 35 to 47), confirmed by central Reading Center grading of fundus photographs., If only one eye is eligible, the non-study eye must have at least microaneurysms only (DR severity level 20), Key, Type 1 or type 2 diabetes., Best-corrected E-ETD"

"Fenofibrate 160mg is an effective treatment for patients with conditions including hypertriglyceridemia, severe fredrickson type v hypertriglyceridemia, and dyslipidemias."

"There are 49 sites running this clinical trial, including Valley Eye Physicians and Surgeons in Ayer, University of North carolina at Chapel Hill in Chapel Hill, and Vitreo-Retinal Associates in Grand Rapids, as well as a number of other locations."

"This particular clinical trial is only open to individuals between 18-80 years old. However, there are 29 active trials for those under 18 and 111 for seniors above 65."

"That is correct, the clinical trial is currently looking for 910 patients from 49 locations. The trial was posted on March 5th, 2021 and was last updated on October 13th, 2022."